Ajinomoto Cambrooke, formerly known as Cambrooke Therapeutics, is a leading provider of therapeutic medical nutrition products. Founded in 2000 by Lynn and David Paolella, parents of children diagnosed with phenylketonuria (PKU), the company is dedicated to developing improved nutritional options for individuals with serious medical disorders. Cambrooke offers a wide range of medical formulas and foods for the management of various medical conditions, and collaborates with academia and industry partners to transform early phase development projects into viable commercial products. With a focus on scientific expertise and clinical evidence, Cambrooke is committed to meeting the complex nutritional requirements of both large and small patient populations. The company has a history of innovation, including being the first to launch natural intact proteins for the dietary management of PKU and Tyrosinemia. In 2021, Cambrooke acquired Nualtra, aiming to create better value for healthcare systems in the UK and Ireland through cost-effective medical nutrition and improved patient experiences. Cambrooke continues to strive for excellence in providing therapeutic medical nutrition solutions.Generated from the website